Hisamitsu Pharmaceutical Co., Inc. (4530.T)
JPY 4437.0
(2.05%)
JPY 4437.0
(2.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 18.34 Billion JPY | -12.74% |
| 2022 | 16.55 Billion JPY | 23.79% |
| 2021 | 13.65 Billion JPY | 5.05% |
| 2020 | 14.75 Billion JPY | -45.94% |
| 2019 | 26.98 Billion JPY | -1.67% |
| 2018 | 28.02 Billion JPY | -11.31% |
| 2017 | 32.35 Billion JPY | -3.66% |
| 2016 | 33.67 Billion JPY | -2.73% |
| 2015 | 36.27 Billion JPY | 1.24% |
| 2014 | 28.14 Billion JPY | -0.82% |
| 2013 | 26.61 Billion JPY | -10.44% |
| 2012 | 39.62 Billion JPY | 0.49% |
| 2011 | 39.37 Billion JPY | -0.07% |
| 2010 | 43.38 Billion JPY | 3.98% |
| 2009 | 37.21 Billion JPY | -1.04% |
| 2008 | 39.1 Billion JPY | 10.08% |
| 2007 | 33.65 Billion JPY | 10.86% |
| 2006 | 29.07 Billion JPY | 9.39% |
| 2005 | 27.52 Billion JPY | 16.94% |
| 2004 | 25.26 Billion JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 6.19 Billion JPY | 12.39% |
| 2024 Q1 | 5.56 Billion JPY | 173.15% |
| 2023 Q1 | 5.71 Billion JPY | 87.28% |
| 2023 Q2 | 5.98 Billion JPY | 4.73% |
| 2023 Q4 | 2.35 Billion JPY | -53.2% |
| 2023 FY | - JPY | -12.74% |
| 2023 Q3 | 5.02 Billion JPY | -15.98% |
| 2022 Q1 | 2.29 Billion JPY | -42.26% |
| 2022 FY | - JPY | 23.79% |
| 2022 Q2 | 6.57 Billion JPY | 186.16% |
| 2022 Q4 | 3.05 Billion JPY | -26.35% |
| 2022 Q3 | 4.14 Billion JPY | -37.03% |
| 2021 Q4 | 3.98 Billion JPY | 117.01% |
| 2021 Q1 | 2.85 Billion JPY | -31.14% |
| 2021 Q2 | 3.98 Billion JPY | 39.52% |
| 2021 FY | - JPY | 5.05% |
| 2021 Q3 | 1.83 Billion JPY | -53.99% |
| 2020 Q3 | 2.41 Billion JPY | -52.7% |
| 2020 FY | - JPY | -45.94% |
| 2020 Q1 | 419 Million JPY | -92.67% |
| 2020 Q2 | 5.1 Billion JPY | 1117.66% |
| 2020 Q4 | 4.14 Billion JPY | 71.94% |
| 2019 Q3 | 9.28 Billion JPY | 19.26% |
| 2019 FY | - JPY | -1.67% |
| 2019 Q1 | 2.86 Billion JPY | -60.39% |
| 2019 Q2 | 7.78 Billion JPY | 171.56% |
| 2019 Q4 | 5.71 Billion JPY | -38.43% |
| 2018 Q3 | 5.41 Billion JPY | -28.51% |
| 2018 FY | - JPY | -11.31% |
| 2018 Q1 | 4.45 Billion JPY | -28.31% |
| 2018 Q4 | 7.23 Billion JPY | 33.75% |
| 2018 Q2 | 7.56 Billion JPY | 70.01% |
| 2017 Q2 | 7.93 Billion JPY | 60.44% |
| 2017 Q1 | 4.94 Billion JPY | -6.71% |
| 2017 FY | - JPY | -3.66% |
| 2017 Q4 | 6.2 Billion JPY | -32.39% |
| 2017 Q3 | 9.18 Billion JPY | 15.71% |
| 2016 Q1 | 5.57 Billion JPY | 22.44% |
| 2016 Q4 | 5.3 Billion JPY | -48.72% |
| 2016 FY | - JPY | -2.73% |
| 2016 Q3 | 10.34 Billion JPY | 47.68% |
| 2016 Q2 | 7 Billion JPY | 25.73% |
| 2015 Q2 | 8.96 Billion JPY | 58.17% |
| 2015 Q4 | 4.54 Billion JPY | -48.62% |
| 2015 Q3 | 8.85 Billion JPY | -1.27% |
| 2015 FY | - JPY | 1.24% |
| 2015 Q1 | 5.67 Billion JPY | -3.24% |
| 2014 FY | - JPY | -0.82% |
| 2014 Q4 | 5.86 Billion JPY | -17.16% |
| 2014 Q3 | 7.07 Billion JPY | -20.73% |
| 2014 Q2 | 8.92 Billion JPY | 33.87% |
| 2014 Q1 | 6.66 Billion JPY | 95.77% |
| 2013 Q3 | 8.66 Billion JPY | -14.56% |
| 2013 Q4 | 3.4 Billion JPY | -60.71% |
| 2013 FY | - JPY | -10.44% |
| 2013 Q1 | 6.73 Billion JPY | -3.82% |
| 2013 Q2 | 10.14 Billion JPY | 50.71% |
| 2012 Q3 | 9.58 Billion JPY | -2.91% |
| 2012 Q2 | 9.87 Billion JPY | 48.79% |
| 2012 FY | - JPY | 0.49% |
| 2012 Q4 | 6.99 Billion JPY | -27.0% |
| 2012 Q1 | 6.63 Billion JPY | -34.56% |
| 2011 Q2 | 9.97 Billion JPY | 10.83% |
| 2011 Q3 | 11.37 Billion JPY | 14.0% |
| 2011 Q4 | 10.13 Billion JPY | -10.83% |
| 2011 FY | - JPY | -0.07% |
| 2011 Q1 | 8.99 Billion JPY | -1.09% |
| 2010 Q2 | 12.4 Billion JPY | 3.08% |
| 2010 Q1 | 12.03 Billion JPY | 56.69% |
| 2010 Q4 | 9.09 Billion JPY | -8.77% |
| 2010 FY | - JPY | 3.98% |
| 2010 Q3 | 9.97 Billion JPY | -19.6% |
| 2009 Q2 | 10.94 Billion JPY | 29.78% |
| 2009 Q1 | 8.43 Billion JPY | 0.0% |
| 2009 FY | - JPY | -1.04% |
| 2009 Q4 | 7.68 Billion JPY | -35.49% |
| 2009 Q3 | 11.9 Billion JPY | 8.8% |
| 2008 FY | - JPY | 10.08% |
| 2007 FY | - JPY | 10.86% |
| 2006 FY | - JPY | 9.39% |
| 2005 FY | - JPY | 16.94% |
| 2004 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 6.02 Billion JPY | -204.601% |
| Takeda Pharmaceutical Company Limited | 874.6 Billion JPY | 97.903% |
| Sumitomo Pharma Co., Ltd. | -281.07 Billion JPY | 106.525% |
| Shionogi & Co., Ltd. | 186.7 Billion JPY | 90.177% |
| Wakamoto Pharmaceutical Co.,Ltd. | 570.97 Million JPY | -3112.066% |
| Nippon Shinyaku Co., Ltd. | 36.29 Billion JPY | 49.463% |
| Kaken Pharmaceutical Co., Ltd. | 12.26 Billion JPY | -49.507% |
| Eisai Co., Ltd. | 103.1 Billion JPY | 82.212% |
| Morishita Jintan Co., Ltd. | 1.29 Billion JPY | -1318.407% |
| Mochida Pharmaceutical Co., Ltd. | 8.97 Billion JPY | -104.391% |
| Fuso Pharmaceutical Industries,Ltd. | 3.67 Billion JPY | -399.728% |
| Nippon Chemiphar Co., Ltd. | 1.4 Billion JPY | -1207.199% |
| Tsumura & Co. | 30.77 Billion JPY | 40.4% |
| Kissei Pharmaceutical Co., Ltd. | 18.72 Billion JPY | 2.03% |
| Torii Pharmaceutical Co., Ltd. | 5.27 Billion JPY | -247.942% |
| Towa Pharmaceutical Co., Ltd. | 35.53 Billion JPY | 48.39% |
| Fuji Pharma Co., Ltd. | 6.88 Billion JPY | -166.492% |
| Zeria Pharmaceutical Co., Ltd. | 17.52 Billion JPY | -4.671% |
| KYORIN Holdings, Inc. | 10.29 Billion JPY | -78.127% |
| Taiko Pharmaceutical Co.,Ltd. | -3.75 Billion JPY | 589.067% |
| Daito Pharmaceutical Co.,Ltd. | 7.55 Billion JPY | -142.817% |
| SymBio Pharmaceuticals Limited | -714 Million JPY | 2668.627% |
| MedRx Co., Ltd | -884.51 Million JPY | 2173.45% |
| Mizuho Medy Co.,Ltd. | 5.53 Billion JPY | -231.269% |
| Solasia Pharma K.K. | -635 Million JPY | 2988.189% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 872.561% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 9.16 Billion JPY | -100.153% |
| Sawai Group Holdings Co., Ltd. | 36.87 Billion JPY | 50.262% |
| Cyfuse Biomedical K.K. | -538.28 Million JPY | 3507.092% |
| Toho Holdings Co., Ltd. | 25.84 Billion JPY | 29.038% |
| Koa Shoji Holdings Co.,Ltd. | 5.1 Billion JPY | -259.492% |